Sitafloxacin is a
fluoroquinolone antibacterial with in vitro activity against a broad range of Gram-positive and -negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. It is approved in Japan for use in a number of
bacterial infections caused by
sitafloxacin-susceptible strains of Staphylococcus spp., Streptococcus pneumoniae, other Streptococcus spp., Enterococcus spp., Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella spp., Enterobacter spp., Serratia spp., Proteus spp., Morganella morganii, Haemophilus influenzae, Pseudomonas aeruginosa, Legionella pneumophila, Peptostreptococcus spp., Prevotella spp., Porphyromonas spp., Fusobacterium spp., Chlamydia trachomatis, Chlamydophila pneumoniae and Mycoplasma pneumoniae. In terms of clinical efficacy, oral
sitafloxacin was noninferior to oral
levofloxacin in the treatment of community-acquired
pneumonia or an infectious exacerbation of chronic
respiratory tract disease, noninferior to oral
tosufloxacin in the treatment of community-acquired
pneumonia, and noninferior to oral
levofloxacin in the treatment of complicated
urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials. Noncomparative studies demonstrated the efficacy of oral
sitafloxacin in otorhinolaryngological
infections,
urethritis in men, C. trachomatis-associated
cervicitis in women and odontogenic
infections.
Gastrointestinal disorders and laboratory abnormalities were the most commonly occurring adverse reactions in patients receiving oral
sitafloxacin. Adverse reactions reported in
sitafloxacin recipients in the active comparator trials were of mild to moderate severity.